PureTech Health

PTCHF · OTC · United States

Share price · PTCHF

$1.56-0.13 (-7.40%) 3M

no price since 18 Aug 2026

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when PTCHF's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 11 Jun 2026-8.7%
  2. 26 May 2026+12.8%
  3. 6 May 2026-12.0%
  4. 1 May 2026+13.8%
  5. 30 Apr 2026-4.1%
  6. 14 Apr 2026+12.1%

    Nothing announced by PTCHF that day or the session before.

  7. 6 Mar 2026-5.8%
  8. 10 Feb 2026-8.2%
  9. 23 Jan 2026+6.9%

    Nothing announced by PTCHF that day or the session before.

  10. 12 Jan 2026+3.2%

    Nothing announced by PTCHF that day or the session before.

Share of unusual movement by asset

For each asset, the share of PTCHF's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
GlyphAllo (allopregnanolone prodrug) (SPT-300)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—17%
Sessions with no dated event—83%

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2
GABA-A receptorSmall molecule
Major Depressive Disorder
Phase 1/2
Galectin-9 (LGALS9)Monoclonal antibody
Acute Myeloid Leukemia

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
March 2027 (1)
GlyphAllo (allopregnanolone prodrug) · SPT-300Phase 2Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
Est. primary completion 2027-03 · NCT07065240 · CT.gov ↗
What to watch
May 2027 (1)
GlyphAllo (allopregnanolone prodrug) · SPT-300Phase 2Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
Est. primary completion 2027-05 · NCT07161700 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 September 2026Topline resultGlyphAllo (allopregnanolone prodrug)Phase 1 driving simulation trial of GlyphAllo met its primary endpoint
Seaport Therapeutics · Source ↗

Financial reports

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$4.8M$69M$281M—-$134M operating cash flowreport ↗
View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-FY$3.3M$96M$191M$17M-$106M operating cash flowreport ↗
2022-FY$16M$152M$150M$9.3M-$179M operating cash flowreport ↗
2021-FY$17M$110M$466M$16M-$158M operating cash flowreport ↗

Insider transactions

This company files with the SEC but has no Section 16 insider reports. This is typical for foreign private issuers, which are exempt from Form 4 reporting.